March 27, 2018
2 min read

Sofosbuvir-based DAAs effective for most genotypes in Chinese patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Sofosbuvir plus ribavirin with or without pegylated interferon was safe and effective in Chinese patients with hepatitis C genotypes 1, 2, 3 and 6, regardless of treatment experience, according to recently published data.

“Both sofosbuvir plus peginterferon/ribavirin for 12 weeks and all-oral sofosbuvir plus ribavirin for 12 to 24 weeks would represent, in China, a clinically significant improvement compared with the current standard of care of peginterferon/ribavirin,” Lai Wei, MD, from the Peking University People’s Hospital, China, and colleagues wrote.

The study comprised 389 patients with HCV. Patients with genotype 1 and those with genotype 6 received combination sofosbuvir (Sovaldi, Gilead Sciences) plus ribavirin for 24 weeks or the combination with PEG-IFN for 12 weeks. Patients with genotype 2 received the sofosbuvir combination for 12 weeks and those with genotype 3 received the combination for 24 weeks.

Patients with genotype 1 achieved a sustained virologic response rate of 95% without PEG-IFN and 94% with PEG-IFN. Patients with genotype 6 had the highest SVR of 100% in those who received combination therapy with PEG-IFN and 97% among those treated without PEG-IFN. Those with genotype 2 achieved a rate of 92% and those with genotype 3 achieved a rate of 95%.

Twenty patients experienced relapse within 12 weeks; however, no patients experienced viral breakthrough during treatment.

Subgroup analysis showed that patients achieved an SVR of 86% or higher regardless of baseline characteristics, including IL28B genotype, baseline HCV-RNA levels and treatment experience. Patients with cirrhosis who received PEG-IFN during treatment had a lower rate of SVR.

The most common adverse events included reticulocyte count (n = 63), pyrexia (n = 60) and anemia (n = 55), which occurred more often among patients treated with PEG-IFN for 12 weeks (94% vs. 84%) and for 24 weeks (94% vs. 78%) than those treated without PEG-IFN. The researchers considered one case of angle closure glaucoma and one case of gastritis to be treatment-related.

“Besides lack of efficacy, the reasons for treatment failure [with PEG-IFN] include discontinuation of treatment due to unmanaged or unmanageable side effects and problems with the monitoring of patients in rural areas,” the researchers wrote. “Overall, sofosbuvir-based therapy resulted in high SVR rates of 92% [or higher].” – by Talitha Bennett

Disclosure: Wei reports he received research grants from AbbVie, Bristol-Myers Squibb and Roche; has served on advisory boards for AbbVie, Allergan, Ascletis, Bristol-Myers Squibb, Galmed, Gilead and Trek; and has served on the speakers bureaus of Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Gilead, Johnson & Johnson and Merck Sharp & Dohme. Please see the full study for the other authors’ relevant financial disclosures.